

Daniel V Catenacci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1205438/publications.pdf>

Version: 2024-02-01

126
papers

10,048
citations

66343

42
h-index

37204

96
g-index

129
all docs

129
docs citations

129
times ranked

11482
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	7.1	1,350
2	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 717-726.	10.7	943
3	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684.	10.7	923
4	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	10.7	620
5	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4284-4292.	1.6	431
6	New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing. <i>Oncologist</i> , 2014, 19, 235-242.	3.7	371
7	Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6496-505.	7.1	313
8	Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.	4.1	289
9	Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1467-1482.	10.7	265
10	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 37-48.	9.4	248
11	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. <i>Nature Medicine</i> , 2018, 24, 968-977.	30.7	196
12	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	7.1	194
13	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021, 7, 895.	7.1	184
14	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837.	5.3	181
15	A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2016, 45, 370-375.	1.1	175
16	Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. <i>PLoS ONE</i> , 2013, 8, e54014.	2.5	174
17	Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2677-2694.	1.6	169
18	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.	7.0	152

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 7098-7112.	7.0	142
20	KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4003.	1.6	134
21	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€“05): a single-arm, phase 1bâ€“2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1066-1076.	10.7	130
22	Nextâ€“generation clinical trials: Novel strategies to address theâ€“challenge of tumor molecular heterogeneity. <i>Molecular Oncology</i> , 2015, 9, 967-996.	4.6	119
23	Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i>-Amplified Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 696-713.	9.4	107
24	Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence. <i>Cancer Discovery</i> , 2011, 1, 573-579.	9.4	105
25	Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 6453-6463.	7.0	92
26	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	7.0	90
27	RON<i>(MST1R)</i> is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2011, 12, 9-46.	3.4	79
28	Tumor genome analysis includes germline genome: Are we ready for surprises?. <i>International Journal of Cancer</i> , 2015, 136, 1559-1567.	5.1	73
29	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019, 24, 1340-1347.	3.7	73
30	Myelodysplastic syndromes: A comprehensive review. <i>Blood Reviews</i> , 2005, 19, 301-319.	5.7	68
31	Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. <i>Oncologist</i> , 2015, 20, 499-507.	3.7	64
32	MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 1155-1164.	2.4	64
33	Randomized double-blind placebo-controlled phase 2 study of beparituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 160-160.	1.6	64
34	Molecular Profiling of Cancerâ€“The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. <i>Seminars in Oncology</i> , 2011, 38, 173-185.	2.2	61
35	Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2014, 20, 1666-1675.	7.0	61
36	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1237-1246.	7.0	61

#	ARTICLE	IF	CITATIONS
37	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2018, 14, 417-430.	2.4	55
38	Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. <i>Future Oncology</i> , 2019, 15, 2073-2082.	2.4	55
39	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2418-2426.	1.6	55
40	Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. <i>PLoS ONE</i> , 2014, 9, e100586.	2.5	52
41	Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. <i>Cancer Discovery</i> , 2021, 11, 308-325.	9.4	49
42	A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2017, 22, 264-271.	3.7	45
43	Gastroesophageal cancer: focus on epidemiology, classification, and staging. <i>Discovery Medicine</i> , 2013, 16, 103-111.	0.5	44
44	Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. <i>Gastric Cancer</i> , 2016, 19, 1066-1079.	5.3	40
45	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2403-2413.	7.0	40
46	Personalized Colon Cancer Care in 2010. <i>Seminars in Oncology</i> , 2011, 38, 284-308.	2.2	35
47	The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. <i>Cancer</i> , 2020, 126, 2525-2533.	4.1	35
48	Differential expression of RON in small and non-small cell lung cancers. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 841-851.	2.8	32
49	MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. <i>Cancer</i> , 2017, 123, 1061-1070.	4.1	32
50	A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAPI-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. , 2013, 1, 8.		30
51	Next-Generation Companion Diagnostics: Promises, Challenges, and Solutions. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 11-13.	2.5	29
52	Toward personalized treatment of advanced biliary tract cancers. <i>Discovery Medicine</i> , 2012, 14, 41-57.	0.5	29
53	A <i>UGT1A1</i> genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. <i>Cancer</i> , 2019, 125, 1629-1636.	4.1	27
54	FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4010-4010.	1.6	27

#	ARTICLE	IF	CITATIONS
55	Evaluation of the Association of Perioperative <i>UGT1A1</i> Genotypeâ€Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma. <i>JAMA Network Open</i> , 2020, 3, e1921290.	5.9	26
56	It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 475-477.	1.6	25
57	Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. <i>Oncologist</i> , 2019, 24, 475-482.	3.7	23
58	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 430-430.	1.6	20
59	Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. <i>Journal of Hematology and Oncology</i> , 2013, 6, 66.	17.0	18
60	Morphologic and molecular analysis of early-onset gastric cancer. <i>Cancer</i> , 2021, 127, 103-114.	4.1	18
61	A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. <i>Investigational New Drugs</i> , 2016, 34, 319-328.	2.6	17
62	Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e88-e95.	3.8	17
63	The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. <i>Cancer</i> , 2020, 126, 2534-2540.	4.1	17
64	Structural Racism and <i>JAMA Network Open</i> . <i>JAMA Network Open</i> , 2021, 4, e2120269.	5.9	17
65	<i>FGFR2</i> -Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. <i>Oncologist</i> , 2019, 24, 1462-1468.	3.7	16
66	Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy. <i>JAMA Oncology</i> , 2020, 6, e193531.	7.1	16
67	MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinomaâ€”Trial in Progress.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS252-TPS252.	1.6	16
68	Update on Gastroesophageal Adenocarcinoma Targeted Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 511-527.	2.2	15
69	Novel Targeted Therapies for Esophagogastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 293-312.	1.5	14
70	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1704-e1729.	3.7	14
71	Expansion platform type II: testing a treatment strategy. <i>Lancet Oncology</i> , The, 2015, 16, 1276-1278.	10.7	13
72	A Subgroup Cluster-Based Bayesian Adaptive Design for Precision Medicine. <i>Biometrics</i> , 2017, 73, 367-377.	1.4	13

#	ARTICLE	IF	CITATIONS
73	Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).. Journal of Clinical Oncology, 2018, 36, 140-140.	1.6	13
74	Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097411.	3.2	12
75	The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. Cancer, 2020, 126, 2553-2560.	4.1	11
76	Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ESMO Open, 2021, 6, 100200.	4.5	11
77	The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now. Journal of Clinical Oncology, 2019, 37, 2177-2178.	1.6	10
78	Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotypeâ€“Guided Dosing. Clinical Cancer Research, 2020, 26, 18-24.	7.0	10
79	Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer.. Journal of Clinical Oncology, 2017, 35, 4067-4067.	1.6	10
80	Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).. Journal of Clinical Oncology, 2019, 37, 91-91.	1.6	10
81	Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 503-507.	4.9	9
82	Keeping Checkpoint Inhibitors in Check. JAMA Network Open, 2019, 2, e192546.	5.9	9
83	A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.. Journal of Clinical Oncology, 2017, 35, TPS219-TPS219.	1.6	9
84	Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).. Journal of Clinical Oncology, 2018, 36, 4030-4030.	1.6	9
85	Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289).. Journal of Clinical Oncology, 2018, 36, TPS198-TPS198.	1.6	9
86	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptorâ€“Amplified Gastroesophageal Cancer: Retrospective Global Experience. Journal of Clinical Oncology, 2022, 40, 2458-2467.	1.6	9
87	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori, 2021, 107, 150-159.	1.1	8
88	Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence. Cancers, 2021, 13, 5929.	3.7	8
89	The Chicago Consensus on peritoneal surface malignancies: Standards. Cancer, 2020, 126, 2516-2524.	4.1	7
90	MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinomaâ€“Trial in progress.. Journal of Clinical Oncology, 2022, 40, TPS371-TPS371.	1.6	7

#	ARTICLE	IF	CITATIONS
91	Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy. JCO Precision Oncology, 2020, 4, 1180-1186.	3.0	6
92	Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.. Journal of Clinical Oncology, 2021, 39, e16063-e16063.	1.6	6
93	Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) ILUSTRO Cohort 3.. Journal of Clinical Oncology, 2021, 39, TPS260-TPS260.	1.6	5
94	Circulating tumor DNA (ctDNA) landscape and prognostic implications in advanced gastroesophageal adenocarcinoma (GEC).. Journal of Clinical Oncology, 2018, 36, 45-45.	1.6	5
95	Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma. ESMO Open, 2022, 7, 100360.	4.5	5
96	Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.. Journal of Clinical Oncology, 2022, 40, TPS365-TPS365.	1.6	5
97	Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas. Cancer Discovery, 2019, 9, 166-168.	9.4	4
98	Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 1777-1785.	1.5	4
99	Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. Journal of Clinical Oncology, 2021, 39, TPS264-TPS264.	1.6	4
100	Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Annals of Surgical Oncology, 2021, 28, 4433-4443.	1.5	4
101	Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. JCO Precision Oncology, 2022, 6, e2100337.	3.0	4
102	How can next-generation diagnostics aid pancreatic adenocarcinoma treatment?. Future Oncology, 2016, 12, 585-588.	2.4	3
103	When Inhibitor MET Biomarker: Postmortem or Initium Novum?. JCO Precision Oncology, 2019, 3, 1-6.	3.0	3
104	FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.. Journal of Clinical Oncology, 2018, 36, TPS4135-TPS4135.	1.6	3
105	Impact of frontline doublet versus triplet therapy on clinical outcomes: Exploratory analysis from the RAINBOW study.. Journal of Clinical Oncology, 2020, 38, 4543-4543.	1.6	3
106	Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.. Journal of Clinical Oncology, 2020, 38, 4561-4561.	1.6	3
107	Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. Journal of Clinical Oncology, 2020, 38, TPS468-TPS468.	1.6	2
108	A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, TPS219-TPS219.	1.6	2

#	ARTICLE	IF	CITATIONS
109	A survey of the population genetic variation in the human kinome. <i>Journal of Human Genetics</i> , 2009, 54, 488-492.	2.3	1
110	Tackling diversity within diversity. <i>Annals of Oncology</i> , 2020, 31, 970-972.	1.2	1
111	A PERFECT Biomarker-focused Study of Neoadjuvant IO for Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3269-3271.	7.0	1
112	Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4069-4069.	1.6	1
113	Evaluating the Value of a New Prediction Model for Gastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2137148.	5.9	1
114	Correlation of circulating tumor DNA (ctDNA) with clinical outcomes in appendiceal cancers (AC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 29-29.	1.6	1
115	Impact of hyperthermic intraperitoneal chemotherapy on genomic heterogeneity of peritoneal metastases in stage IV gastroesophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 312-312.	1.6	1
116	386 HIGH NUMBERS OF PORTAL VENOUS CIRCULATING TUMOR CELLS ACQUIRED VIA EUS PROVIDE PROGNOSTIC ASSISTANCE FOR PROGRESSION FREE SURVIVAL IN PANCREATICOBILIARY CANCERS. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB78-AB79.	1.0	0
117	Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, irinotecan, and ctDNA. <i>Clinical Cancer Research</i> , 2021, 27, clincanres.2777.2021.	7.0	0
118	Molecular profiling of advanced pancreatic cancer (PC) patients from a phase I/II study using circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4124-4124.	1.6	0
119	Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4068-4068.	1.6	0
120	A phase 2 trial of CRS-207 and pembrolizumab in adults with recurrence of metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS200-TPS200.	1.6	0
121	Safety and tolerability of 5-FU, irinotecan (IRI), and nab-paclitaxel (FOLFIRABRAX) with genotype-guided dosing of IRI in previously untreated patients with advanced gastrointestinal (GI) malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 423-423.	1.6	0
122	Analysis of DNA damage response (DDR) genes and tumor mutational burden (TMB) across 17,486 carcinomas of the tubular GI tract: Implications for therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 43-43.	1.6	0
123	Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4063-4063.	1.6	0
124	Safety and tolerability of FOLFIRABRAX [5-Fluorouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consortium.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16241-e16241.	1.6	0
125	CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS377-TPS377.	1.6	0
126	Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for advanced upper GI cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 316-316.	1.6	0